Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Garners New Indication and New Product Formulation Approvals from U.S. FDA for Children with Neurogenic Detrusor Overactivity

03/29/2021 | 09:32am EDT

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') announced today that the U.S. Food and Drug Administration (FDA) approved Myrbetriq (mirabegron extended-release tablets) for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq Granules for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older.

The FDA also granted pediatric exclusivity for Myrbetriq, resulting in an additional six month period of market exclusivity.

Myrbetriq and Myrbetriq Granules are first-in-class to now be FDA-approved for children with NDO. Treatment options for NDO have been limited or invasive, including scheduled toileting, catheterization, or surgery.1 If left untreated, NDO can lead to the deterioration of urinary tract function at an early age.2

'With this latest approval, Astellas is bringing forward a new treatment option for children impacted by NDO, an especially vulnerable patient population with high unmet need,' said Salim Mujais, M.D., senior vice president and head, Medical Specialties, Astellas. 'This approval marks a significant milestone for patients living with this rare but serious bladder condition that can cause unwanted accidents.'3

NDO is a type of bladder dysfunction caused by nerve damage and is marked by uncontrolled bladder contractions that can lead to symptoms of urinary frequency, urgency and incontinence.1 Eighty-five percent of children with NDO have spina bifida, a congenital spinal cord defect.3

Myrbetriq tablets (mirabegron extended-release tablets) are currently available in the U.S.

Myrbetriq Granules (mirabegron for extended-release oral suspension) were developed for ease of administration in younger children with NDO, or children with NDO who may have difficulty swallowing tablets, and will be available in the U.S. by the end of 2021.

'Astellas is a long-time leader in the field of urologic health and is committed to advancing the treatment of bladder conditions that adversely impact the lives of patients,' continued Mujais. 'Since its initial approval nine years ago, Myrbetriq has been used to treat nearly 18 million adult patients worldwide with urological conditions.'4

The approval for the NDO indication was based on findings from a Phase 3 pivotal study that evaluated the efficacy, safety, tolerability and pharmacokinetics of mirabegron in children and adolescents (aged 3 to

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
07/30ASTELLAS PHARMA : and Minovia Therapeutics Announce Strategic Collaboration for ..
BU
07/30Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel ..
CI
07/29ASTELLAS PHARMA : Financial Results (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Presentation Material for Information Meeting (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Supplementary Documents (Q1/FY2021)
PU
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplem..
CI
07/15Piers Morgan Joins Pharnext's Board of Directors
DJ
07/15Piers Morgan rejoint le Conseil d'Administration de Pharnext
DJ
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 ..
CI
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 S..
CI
More news
Financials
Sales 2022 1 324 B 12 073 M 12 073 M
Net income 2022 193 B 1 760 M 1 760 M
Net cash 2022 478 B 4 354 M 4 354 M
P/E ratio 2022 16,5x
Yield 2022 2,79%
Capitalization 3 324 B 30 343 M 30 309 M
EV / Sales 2022 2,15x
EV / Sales 2023 1,89x
Nbr of Employees 15 455
Free-Float 99,0%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 1 794,00 JPY
Average target price 2 455,38 JPY
Spread / Average Target 36,9%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.12.55%30 343
JOHNSON & JOHNSON10.15%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.22.77%255 703
ELI LILLY AND COMPANY55.45%232 701
NOVARTIS AG-0.20%224 638